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INTRODUCTION 
Pleural effusion is the abnormal collection of fluid in the pleural space. It is classified 
into exudate and transudate based on Light’s criteria. The causes and management of 
transudative effusion is simple when compared with exudative effusion. The common exudative 
effusions encountered in clinical practice are Tuberculosis, Malignant, Parapneumonic or 
associated with Collagen vascular disease. TB pleural effusion is seen in more than 90%. 
Definitive diagnosis of the etiology of exudative pleural effusion is not made in majority of the 
cases because of non-availability of pleural biopsy in most centres. In India,an exudative pleural 
effusion is considered Tuberculous and started on Antituberculous therapy(ATT). 
Pleural fluid AFB demonstration is virtually always negative, culture of fluid could be 
positive in < 25%,histopathological examination(HPE) of pleural biopsy could be positive in 
80% whereas HPE and culture of pleural biopsy increases diagnostic efficacy to 90%.  
Adenosine deaminase(ADA) is considered a valuable tool in the diagnosis of Extra-pulmonary 
Tuberculosis. Various studies using ADA  as a diagnostic tool for tuberculous pleural effusion 
quote that the sensitivity and specificity of ADA in pleural fluid ranges between 47.1%-100% 
and 50%-100% respectively. A Cochrane meta-analysis review of forty articles on ADA in 
pleural fluid shows that the test results for ADA with cutoff value > 40 U/L  derived from the 
summary receptor operator curve(SROC) was 92.2% for both sensitivity and specificity. ADA 
value > 40 U/L with a lymphocytic effusion Lymphocyte/Neutrophil(L/N)ratio >0.75 is 
considered diagnostic of TB pleural effusion. 
This study was undertaken to evaluate the role of ADA and L/N ratio in the  diagnosis of 
Tuberculous pleural effusion in patients with exudative effusion.   
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AIM OF THE STUDY 
1.To evaluate the role of ADA and L/N ratio in the diagnosis of tuberculous pleural effusion in 
patients with exudative pleural effusion. 
2. To analyze the cause of nontuberculous exudative pleural effusion. 
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REVIEW OF LITERATURE 
The pleura is the serous membrane that covers the lung parenchyma, the mediastinum, 
the diaphragm, and the rib cage. The visceral pleura covers the lung parenchyma at its points of 
contact with the chest wall, diaphragm, and mediastinum and also in the inter-lobar fissures. The 
parietal pleura lines the inside of the thoracic cavities. A film of fluid (pleural fluid) is normally 
present between the parietal and the visceral pleura which acts as a lubricant and allows the 
visceral pleura to slide along the parietal pleura during respiratory movements and prevents 
friction. Pleura covers the apices of  the lungs one inch above the medial third of the clavicle. 
The anterior margin converge,pass behind the sternoclavicular joints and come into apposition at 
the lower border of the manubrium sterni1. Anterior margin remains in apposition till 4th  costal 
cartilage,right pleura continues vertically, but the left pleura arches laterally and descend lateral 
to the border of the sternum. Each turn laterally at the 6th costal cartilage and passes around the 
chest wall crossing the midclavicular line at 8th rib and mid axillary line at 10th rib. It crosses the 
12th rib at the lower border of sacrospinalis muscle and passes horizontally to the lower border of 
the 12th thoracic vertebrae2. 
The arterial supply and lymphatic drainage of parietal pleura are intercostals, internal 
thoracic and musculophrenic arteries and nodes respectively. The nerve supply is from the 
intercostal and phrenic nerves. The arterial supply and drainage of visceral pleura is by branches 
of pulmonary artery and systemic and pulmonary venous system respectively. Its lymphatics join 
with those of the lung and innervated by autonomous nervous system. Parietal pleura is pain 
sensitive whereas visceral pleura is pain insensitive. 
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CHARACTERISTICS OF PLEURAL FLUID3: 
 Volume:The total pleural fluid volume in nonsmoking human is 0.26 ± 0.1 mL/kg .4 
Cells:The mean WBC count is 1,716 cells/mm3 and the mean RBC count was approximately 700 
cells/mm3 of which approximately 75% are macrophages and 25% lymphocytes, with 
mesothelial cells, neutrophils, and eosinophils accounting for less than 2% each 4.  
Physicochemical Factors:A small amount of protein is normally present in the pleural fluid5. 
Protein composition of pleural fluid is similar to that of the corresponding serum, except that 
low-molecular-weight proteins such as albumin are present in relatively greater quantities in the 
pleural fluid6.  
 
PLEURAL FLUID FORMATION3: 
Fluid that enters the pleural space can originate in the pleural capillaries, the interstitial 
spaces of the lung, the intrathoracic lymphatics, the intrathoracic blood vessels, or the peritoneal 
cavity. 
Pleural Capillaries 
The movement of fluid between the pleural capillaries and the pleural space is believed to 
be governed by Starling's law of transcapillary exchange7
 
where [Q with dot above]f is the liquid movement; Lp is the filtration coefficient/unit area or the 
hydraulic water conductivity of the membrane; A is the surface area of the membrane; P and Ï€ 
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are the hydrostatic and oncotic pressures, respectively, of the capillary (cap) and pleural (pl) 
space; and Ïƒd is the solute reflection coefficient for protein, a measure of the membrane's ability 
to restrict the passage of large molecules  
The net gradient across parietal pleura is 35 - 29 = 6 cm H2O, favoring the movement of 
fluid from the capillaries in the parietal pleura to the pleural space. The net gradient for fluid 
movement across the visceral pleura in humans is probably close to zero, but this has not been 
demonstrated. 
 
 
Figure 1: showing the gradiant across the pleura for fluid movement. 
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Interstitial Origin: 
The pulmonary interstitial space is probably the origin of the pleural fluid in patients with 
congestive heart failure. Either high-pressure or high-permeability pulmonary edema can lead to 
the accumulation of pleural fluid. 
Peritoneal Cavity: 
Pleural fluid accumulation can occur if there is free fluid in the peritoneal cavity and if 
there are openings in the diaphragm as the pressure in the pleural cavity is less than the pressure 
in the peritoneal cavity. The peritoneal cavity is the origin of the pleural fluid in hepatic 
hydrothorax, Meigs' syndrome  and peritoneal dialysis6. 
Thoracic Duct or Blood Vessel Disruption: 
If the thoracic duct is disrupted, lymph will accumulate in the pleural space, producing a 
chylothorax. The rate of fluid accumulation with chylothorax can be more than 1,000 mL/day. 
when a large blood vessel in the thorax is disrupted owing to trauma or disease, blood can 
accumulate rapidly in the pleural space, producing a hemothorax. 
DRAINAGE OF PLEURAL FLUID: 
The amount of pleural fluid formed daily in a 50-kg individual would be approximately 
15 mL8.  The pleural space is in communication with the lymphatic vessels in the parietal pleura 
by means of stomas in the parietal pleura. Proteins, cells, and all other particulate matter are 
removed from the pleural space by these lymphatics in the parietal pleura3. The amount of fluid 
that can be cleared through these lymphatics is substantial to the order that a normal 60-kg 
individual should have a lymphatic drainage from each pleural space on the order of 20 mL/hr or 
7 
 
500 mL/day majority of which occurs through parietal pleura and rest through visceral pleura9.  
The capacity of the lymphatics to remove fluid exceeds the normal rate of fluid formation by a 
factor of  20. 
PATHOGENESIS OF PLEURAL EFFUSIONS: 
Pleural fluid accumulates when the rate of pleural fluid formation exceeds the rate of 
pleural fluid absorption. 
1. Increased pleural fluid formation 
 Increased interstitial fluid in the lung 
o Left ventricular failure, Pneumonia 
 Increased intravascular pressure in the pleura 
o Right or Left ventricular failure, Superior vena cava syndrome 
 Increased permeability of the capillaries 
o Pleural fluid inflammation 
 Increased pleural fluid protein level 
 Decreased pleural pressure 
o Lung collapse or Atelectasis 
 Increased fluid in peritoneal cavity 
o Ascitis or Peritoneal dialysis 
 Disruption of thoracic duct or blood vessels in the thorax 
2. Decreased pleural fluid absorption 
 Obstruction of lymphatics draining the pleura 
 Increased systemic vascular pressure 
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o SVC syndrome, Right ventricular failure 
 Disruption of aquaporin system in the pleura 
EFFECTS OF EFFUSION ON THE PLEURAL PRESSURE3: 
Pleural effusion disrupts the balance between pulmonary and thoracic forces and hence 
increases pleural pressure. It affects the function on various intra thoracic structures adversely.  
Pleural effusion causes following changes: 
Reduction in volume of lung. 
Reduction in FEV1 and FVC. 
Reduction in gas exchange causing hypoxemia. 
Doming, flattening or inversion of the diaphragm leading to dyspnea. 
Reduced exercise tolerance. 
Reduced cardiac output. 
 
A long standing effusion of any cause adds to the discomfort of the patient and has the 
potential threat of pleural calcification which can seriously affect the functioning of the lung. So 
it is essential that effusion should be identified and treated appropriately. 
CLINICAL MANIFESTATIONS OF PLEURAL EFFUSION: 
Minimal pleural effusion may be asymptomatic and detected by routine examination or 
radiological means.  
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Moderate-to-large amounts of pleural fluid produces following symptoms: 
 Chest pain that can be pleuritic or dull aching 
 Dry nonproductive cough 
 Breathlessness 
 Fever 
 Other symptoms related to the underlying cause. 
PHYSICAL FINDINGS IN PLEURAL EFFUSION: 
Inspection of chest wall might show enlargement of hemithorax with bulging and reduced 
movements on the side of fluid accumulation. Displacement of trachea and cardiac apex may be 
noted. Palpation will reveal attenuated or absent vocal fremitus and help in  delineating the 
extent of the effusion better than by percussion,which will reveal a stony dullness. Light 
percussion is preferred to delineate the effusion. Auscultation characteristically reveals decreased 
or absent breath sounds. Near the superior border of the fluid, breath sounds may be accentuated 
and take on a bronchial character,egophony and whispering pectoriloquy which is due to 
increased conductance of breath sounds through the partially atelectatic lung compressed by the 
fluid7 Auscultation may also reveal a pleural rub. Abdomen and other systems should be 
examined to identify the cause. 
 
 
 
10 
 
APPROACH TO THE PATIENT 2,3: 
The first step in the evaluation of pleural effusion is to differentiate if its an exudate or a 
transudate. An effusion meeting any one of the three Light’s criteria is classified as exudative, 
whereas transudative effusion will not meet any criteria.  
The disadvantage in utilizing Light’s criteria is that,it can false-positively classify a 
transudative pleural effusion as exudative in nearly 20% of the cases. If the effusion is 
transudative, the underlying cause is treated. If the effusion is exudative with light’s criteria and 
there is a strong possibility that the effusion is transudative, the next logical step is to calculate 
Serum pleural fluid protein gradient(SPPG). If SPPG is >3.1, the effusion is considered 
transudative.  
An exudative effusion is aspirated and analysed for gross appearance, glucose, cytology, 
cell count, Lactate DeHydrogenase(LDH), staining and culture for organisms and AFB. Special 
tests like serum amylase, pleural fluid amylase, pleural fluid NT-pro brain natriuretic peptide(NT 
Pro BNP) is done as according to clinical scenario. 
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Blunting of costophrenic angle NO 
Pleural effusion unlikely 
Lateral decubitus radiograph, Ultrasound, Chest CT 
Fluid thickness > 10 mm No Observe 
Diagnostic thoracocentesis 
Any of the following met? 
PF/serum protein > 0.5 
PF/serum LDH > 0.6 
PF LDH > 2/3 upper limit of serum 
normal 
NO Transudate 
Treat CHF/ Cirrhosis 
Probable exudate 
Patient has CHF/Cirrhosis? 
Exudate 
NO 
YES 
NO 
Serum-pleural fluid protein gradient > 3.1 
Appearance of pleural fluid 
Pleural fluid Glucose, Cytology, Cell 
count and differential 
Pleural fluid marker for TB 
YES 
Treat CHF/ Cirrhosis 
Suspect pleural disease 
Pt with abnormal chest radiograph 
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CLASSIFICATION OF PLEURAL EFFUSION3: 
I. Transudative pleural effusion 
A. Congestive cardiac failure 
B. Cirrhosis 
Pleural fluid cytology 
Negative Positive Pleural malignancy 
Pleural fluid differential 
Predominant PMNs Predominant lymphocytes 
Acute pleural process 
Parenchymal infilterates 
Chronic pleural process 
ADA or IFN  TB Positive 
YES NO 
Parapneumonic 
effusion 
Negative CT angiogram Negative Abdominal CT or 
USG 
Positive 
Patient improving 
Positive 
GI Disease Pulmonary embolism 
YES NO 
Observe 
Consider thoracoscopy, unusual 
causes of pleural effusion 
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C. Nephrotic syndrome 
D. SVC obstruction 
E. Urinothorax 
F. Fontan procedure 
G. Myxedema 
H. Peritoneal dialysis 
I. Glomerulonephritis 
J. Hypoalbuminemia 
II. Exudative effusion 
A. Infection 
1. Tuberculosis 
2. Bacterial 
3. Viral 
4. Fungal 
5. Parasitic 
B. Malignancy 
1. Bronchogenic carcinoma 
2. Mesothelioma 
3. Metastatic diseases 
4. Lymphoma 
C. Pulmonary embolism 
D. Gastrointestinal diseases 
  1. Pancreatic disease 
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 2. Intrahepatic diseases 
 3. Intrasplenic abscess 
 4. Subphrenic abscess 
 5. Post variceal endotherapy 
 6. Esophageal perforation 
E. Cardiac diseases 
 1. Post Coronary Artery Bypass Graft(CABG) surgery 
 2. Dressler’s syndrome{post Myocardial Infarction(MI) pleurisy} 
 3. Pericardial diseases 
F. Collagen vascular diseases 
 1. Rheumatoid pleurisy 
 2. Systemic lupus erythematosis 
 3. Sjogren’s syndrome 
 4. Wegener’s granulomatosis 
 5. Drug induced lupus 
 6. Churg strauss syndrome 
G. Obstetric and gynaecological cases 
 1. Ovarian hyperstimulation syndrome 
 2. Meig’s syndrome 
 3. Postpartum effusion 
 4. Endometriosis 
H. Drugs 
 1. Dantrolene 
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 2. Amiodarone 
 3.Methysergide 
 4. Nitrofurantoin 
 5. Interleukin 2 
 6. Methotrexate 
 7. Procarbazine 
I. Miscellaneous 
1. Asbestosis 
2. Uraemia 
3. Sarcoidosis 
4. Amyloidosis 
5. Yellow nail syndrome 
6. Drowning 
7. Whipple’s disease 
8. Heamothorax 
9. Chylothorax 
10. Iatrogenic 
 
 
Radiological appearences of pleural effusion: 
Earliest collection of fluid occurs between the inferior surface of the lung and the 
diaphragm, particularly posteriorly. As more fluid accumulates, the fluid spills out into the 
Figure 1: Chest radiograph PA view showing typical appearance of fluid.
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costophrenic sinuses posteriorly, laterally, and anteriorly. Approximately 175 ml of pleural fluid 
is needed to cause blunting of costophrenic angle in a PA film and 75 ml of fluid can produce 
abnormality in lateral view. Lateral decubitus film is occasionally useful. Nearly 1000 ml of fluid 
should be present in pleural space to produce radiological appearance of moderate pleural 
effusion. In the PA projection , the density of the fluid is high laterally and curves gently 
downward and medially with a smooth, meniscus-shaped upper border to terminate at the 
mediastinum. At times substantial amounts of pleural fluid (more than 1,000 mL) can be present 
in infrapulmonary location without spilling into the costophrenic sulci  called subpulmonic or 
infrapulmonary pleural effusions. Although the posterior costophrenic angle is usually blunted, 
at times it is perfectly clear16. Suspicion of subpulmonic effusion should prompt ordering for 
decubitus film. Interlobar effusion, also called vanishing tumour, that occupies interlobar space, 
occur in cardiac failure which diminishes with diuretic therapy. 
Ultrasonogram: 
Ultrasonogram is more efficient than chest radiography for demonstrating pleural 
effusion. Ultrasound can be used to assess the thickness of the parietal pleura and identify pleural 
nodules and focal pleural thickening11. Septations are better visualized on ultrasonogram than 
with computed tomogram(CT). 
Ultrasonogram colour Doppler is used to demonstrate  echogenic particles in pleural space that 
move in response to respiratory cycle. This sign called Fluid Colour sign11, is seen in pleural 
effusion and differentiates it from pleural thickening.  
Computed tomography: 
Figure 2: Chest radiograph PA view showing Subpulmonic effusion on the left 
side
Figure 3: Left  lateral decubitus film of this patient showing free 
pleural fluid
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CT is effective in demonstrating abnormalities in the lung parenchyma that are obscured 
on the conventional chest radiograph and can help to distinguish benign and malignant effusions. 
CT examinations also provide additional information concerning the effects of a pleural effusion 
on the underlying lung3.  
Contrast enhanced CT scanning is more useful in differentiating between benign and malignant 
effusion. In one study of 146 patients with pleural disease, the following findings (with their 
sensitivities and specificities) were suggestive of malignancy: pleural nodularity (37%/97%), 
pleural rind (22%/97%), mediastinal pleural involvement (31%/85%) and pleural thickening 
greater than 1 cm (35%/87%)12. Traill et al.13 reported that 27 of 32 patients with malignant 
pleural effusion had pleural nodularity or irregularity or pleural thickness greater than 1 cm 
whereas none of 8 patients with benign disease met these criteria. 
Pleural fluid aspiration: 
Diagnostic thoracocentesis should be done with a fine bore needle(21G) and 50 ml 
aspirated and analysed in sterilized containers for glucose, protein, cell count, Gram stain, AFB 
stain, microbiological culture, LDH, ADA and cytology. Atleast 20 ml of freshly collected 
sample is sent in a citrated bottle for cytologic examination. The nature and gross appearance of 
fluid is noted in all cases. 
Pleural fluid glucose: 
The routine measurement of the pleural fluid glucose level is recommended because the 
patients with a reduced (<60 mg/dL) pleural fluid glucose have one of four conditions: 
parapneumonic effusion, malignant pleural effusion, tuberculous pleuritis, or rheumatoid pleural 
effusion10. Other rare causes of a low glucose pleural effusion include paragonimiasis, 
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hemothorax, Churg-Strauss syndrome, urinothorax, and occasionally lupus pleuritis. Most 
patients with a reduced pleural fluid glucose level also have a reduced pleural fluid pH and an 
increased pleural fluid LDH level. Laboratory errors in the performance of one of these three 
tests should be suspected when these relationships are not maintained. 
Patients with either parapneumonic effusions or tuberculous pleuritis may have an acute 
illness. Most patients with parapneumonic effusions have predominantly neutrophils in their 
pleural fluid, whereas most patients with tuberculous pleuritis have predominantly lymphocytes. 
Patients with subacute or chronic symptoms and a low pleural fluid glucose level may 
have malignant pleural disease, rheumatoid disease, tuberculosis, or even a chronic bacterial 
infection. The pleural fluid cytology is usually positive for malignant cells in patients with a 
malignant pleural effusion and a low pleural fluid glucose level. The pleural fluid marker for 
tuberculosis should be positive with tuberculous pleuritis and neutrophils should predominate in 
the pleural fluid if a acute bacterial infection is present. 
Pleural fluid lactate dehydrogenase: 
The pleural fluid LDH is a reliable indicator of the degree of pleural inflammation and is 
helpful in differentiating between transudative and exudative effusion. If, with repeated 
thoracentesis, the pleural fluid LDH level increases, the degree of inflammation in the pleural 
space is becoming progressively worse and one should be aggressive in pursuing a diagnosis. 
Pleural fluid cytology: 
Cytologic examination of the pleural fluid is a fast, efficient and minimally invasive means in 
suspected malignancy. The percentage of malignant pleural effusions that are diagnosed with 
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cytology has been reported to be anywhere between 40% and 87%. Almost all adenocarcinomas 
are diagnosed with cytology, but the yield is less with squamous cell carcinoma, Hodgkin's 
disease, and sarcomas. The greater the tumor burden in the pleural space, the more likely the 
cytology is to be positive. 
Thoracoscopy: 
Thoracoscopic procedures should be used only when the less invasive diagnostic methods 
have not yielded a diagnosis. If the patient has malignancy, thoracoscopy will establish the 
diagnosis more than 90% of the time and the diagnosis of mesothelioma is probably best made 
with thoracoscopy. Thoracoscopy can also establish the diagnosis of tuberculosis 11,14. 
Bronchoscopy: 
Bronchoscopy is useful in the diagnosis of pleural effusion only if one or more of the 
following four conditions are present 15.  
a) A pulmonary infiltrate in chest radiograph or chest CT scan.  
b) Hemoptysis is present; hemoptysis in the presence of a pleural effusion is suggestive of an 
endobronchial lesion (or pulmonary embolism). 
 c) The pleural effusion is massive, that is, it occupies more than three fourths of the hemithorax.  
d) The mediastinum is shifted toward the side of the effusion. In this situation, an endobronchial 
lesion is probable. 
 Percutaneous pleural biopsy3: 
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Percutaneous pleural biopsy is of great value in the diagnosis of malignant and 
granulomatous diseases of the pleura, more so when the analysis of pleural fluid is inconclusive. 
In tuberculous pleural effusion histology(HPE) of pleural biopsy could be positive in 80% 
whereas HPE and culture of pleural biopsy increases diagnostic efficacy to 90%. 
Blind percutaneous pleural biopsy is done using Abram’s needle. The procedure can be 
done under local anaesthesia or sedation. To improve the diagnostic efficacy atleast four samples 
should be taken and it is recommended to take samples from single site as multiple site biopsy 
does not increase the diagnostic yield2. Cope’s needle is less commonly used. 
TUBERCULOUS PLEURAL EFFUSION: 
In a country that is endemic to tuberculosis, tuberculous pleuritis should be considered in 
any patient with an exudative pleural effusion. Tuberculous pleural effusion may be the sequel to 
a primary infection acquired 6 to 12 weeks previously or it may represent reactivation TB16.  The 
tuberculous pleural effusion is thought to result from rupture of a subpleural caseous focus in the 
lung into the pleural space17. It is probable that delayed hypersensitivity also plays a large role in 
the development of tuberculous pleural effusions in humans. The mycobacterial cultures of the 
pleural fluid from most patients with tuberculous pleural effusions are negative18,19,20. 
Tuberculous pleuritis most commonly manifests as an acute illness. 35% present with 
initial symptoms of less than 1 week in duration, whereas 70% are symptomatic for less than a 
month 21.  70% have cough, usually nonproductive, and most 75% have chest pain, usually 
pleuritic in nature22,24. Most patients are febrile, but a normal temperature does not rule out the 
diagnosis. Tuberculous effusion is usually unilateral and can be of any size. In 20% of patients 
with pleural effusions secondary to TB25, coexisting parenchymal disease is radiologically 
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visible. The pleural effusion is almost always on the side of the parenchymal infiltrate. 
Tuberculin test may be negative in upto 30% of the cases. 
Pleural Fluid Examination: 
A TB pleural effusion is typically clear and straw colored; however, it can be turbid or 
serosanguinous but is virtually never grossly bloody. The effusion is virtually always an 
exudate18,26,27. Pleural fluid glucose concentration is >60mg/dL in 80 to 85% of cases. Pleural 
fluid glucose is < 30 mg/dL in approximately 15% of cases. Although in the initial stage of 
illness (up to first 2 weeks), the differential cell count may reveal predominantly neutrophils21, 
serial thoracenteses show a shift toward lymphocyte predominance. Old  literature suggests that 
> 5%mesothelial cells in pleural fluid are rarely compatible with TB pleural effusions. This 
finding is most likely the result of chronic pleural inflammation that prevents exfoliation of 
mesothelial cells into pleural cavity. However,there have been case reports of TB pleural 
effusions with numerous mesothelial cells analogous to reports in HIV-infected individuals28. 
Similarly,pleural fluid eosinophils > 10% considerably reduces the probability of TB unless the 
patient has a concomitant pneumothorax or a previous traumatic thoracentesis that has resulted in 
pleural space hemorrhage.24 Without treatment, tuberculous pleuritis usually resolves 
spontaneously, only to return as active TB at a later date29. 
Pleural Fluid Smear and Culture: 
Direct examination of pleural fluid by Zeihl-Neelsen staining requires bacillary densities 
of 10,000/mL and, therefore, detects acid-fast bacilli(AFB) in > 10% of cases18,25,30,31. However, 
in patients with HIV coinfection, the yield of pleural fluid microscopy is > 20%33. Culture 
requires a minimum of 10 to 100 viable bacilli and, therefore, is more sensitive with a yield 
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ranging from 12 to 70%, with the majority of series showing diagnostic yields of < 30% 
18,19,31,32,25
. Sensitivity of mycobacterial culture can be improved by bedside inoculation of 
pleural fluid and by using liquid culture media or BACTEC system33. Moreover, the use of 
radiometric mycobacterial culture systems (BACTEC-460; Becton Dickinson; Rockville, MD) 
yields results more rapidly than the conventional method (18 days vs 33 days)35,23. 
ADENOSINE DEAMINASE: 
ADA is the enzyme that catalyzes the conversion of adenosine to inosine. ADA is a 
predominant T-lymphocyte enzyme, and its plasma activity is high in diseases in which cellular 
immunity is stimulated. ADA is involved in the proliferation and differentiation of lymphocytes, 
especially T lymphocytes. They release ADA when stimulated in the presence of live 
intracellular microorganisms35. For this reason, ADA has been looked on as a marker of cell-
mediated immunity and, in particular, as a marker of the activation of T lymphocytes. 
There are several isoforms of ADA, but the prominent ones are ADA1 and ADA2. ADA-
1 has roughly equal affinities for adenosine and 2'-deoxyadenosine, with a 2'-deoxyadenosine 
deaminase/ ADA activity ratio of approximately 0.75 . ADA-2 has much greater affinity for 
adenosine (2'- deoxyadenosine deaminase/ADA activity ratio approximately 0.25), and is found 
only in macrophages34, which release it when stimulated by the presence of live micro-organisms 
in their interior [9].ADA1 is present in all cells, whereas ADA2 is found only in monocytes and 
macrophages.36   
ADA2 is the predominant isoform in the tuberculous pleural effusion, accounting for 
88% (median) of total ADA activity, whereas ADA1 is elevated in empyema, accounting for 
70% (median) of total ADA activity37. This would suggest that ADA2 is the more efficient 
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marker of tuberculous pleural effusion. However, in clinical practice, the difference in the use of 
total ADA and isoform ADA2 is not significant. In fact, there is an advantage in the 
measurement of total ADA because of its low cost and rapid turnover. ADA1 activity is 
determined by subtracting ADA2 from total ADA. The measurement of ADA2 is almost 10 
times more expensive and is not available routinely except for research purposes38.  
Various methods are available for analyzing ADA ,the most frequently reported method 
being the colorimetric ADA assay described by Guisti and Galanti39.  Blake-Berman method 40, 
which had the same diagnostic properties as the Giusti-Galanti method and Carilaos-Gakis41 
method are the other methods available. Consequently, when interpreting results, physicians 
should be conscious of the differing cutoff levels that can occur with the different methods of 
ADA analysis42. Also ADA levels in pleural fluid maintained at ambient temperature, as reported 
by Miller et al,43 will decrease with time. As they elegantly demonstrated in their study, the 
addition of glycerol and ethylene glycol or glycerol and sodium sulfate to pleural fluid stabilizes 
ADA levels for up to 3 weeks at 37°C, obviating the need to freeze or refrigerate the specimens 
while awaiting analysis.  
Piras and colleagues44 for the first time in 1978 reported high levels of ADA in patients 
with TB pleural effusions. 
The reported diagnostic cutoff value for ADA varies from 40 to 60 U/L,45-50  and 
choosing a lower value will increase sensitivity at the expense of specificity. In a country like 
ours where the prevalence of tuberculosis is high, ADA cutoff of 40 U/L increases the sensitivity 
and negative predictive value of the test51. ADA levels in nontuberculous lymphocytic pleural 
effusions seldom exceed the cut-off set for tuberculous effusions. Low ADA levels in 
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lymphocytic pleural effusions virtually exclude the diagnosis of tuberculosis. The higher the 
pleural fluid ADA level, the more likely the patient is to have tuberculous pleuritis. 
Ocana et al.52 measured the pleural fluid ADA levels in 221 pleural or peritoneal 
effusions. All patients with a pleural fluid ADA level above 70 U/L had TB, whereas no patient 
with a pleural fluid ADA level below 40 U/L had tuberculous pleuritis.  
Ferrer et al.53 followed up 40 patients with undiagnosed pleural effusions and a pleural 
fluid ADA level below 43 U/L for a mean of 5 years and reported that none of the patients 
developed TB.  
Lee et al.54 measured the pleural fluid ADA in 106 patients with lymphocytic pleural 
effusions not due to TB, including 45 postâ€“coronary artery bypass pleural effusions and 26 
malignant pleural effusions. They reported that only 3 of the 106 fluids (3%) had ADA levels 
above 40 U/L54. The three patients included two with lymphoma and one with a late complicated 
parapneumonic effusion.  
Jimenez Castro et al.36measured the pleural fluid ADA levels in 410 lymphocytic 
nontuberculous pleural fluids and found that the ADA was above 40 U/L in only 7 (1.7%). The 
negative predictive value of ADA for the diagnosis of pleural tuberculosis was 99%  in the group 
of lymphocytic pleural effusions. In five of these seven patients ADA1 and ADA2 were 
measured, and in all these cases (100%) ADA1/ADAp correctly classified these lymphocytic 
effusions as nontuberculous. 
L. Valdés, E. SanJosé, D. Alvarez, J.M. Valle et al46.,studied 350 patients with 
tuberculous pleural effusion and found that with a cutoff of 40 U/L,ADA has a sensitivity of 
100%, specificity of 92% and efficiency 93%. They concluded that high total ADA activity in 
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tuberculous pleural effusions is due mainly to an increase in ADA-2, and therefore, originated 
from the only known source monocytes and macrophages; ADA-2 is a more efficient diagnostic 
marker of tuberculous pleurisy than total ADA activity, although the difference is not statistically 
significant; and among effusions with high total ADA the 2'-deoxyadenosine deaminase/ADA 
activity ratio differentiates tuberculous effusions from empyemas and parapneumonic effusions, 
but fails to discriminate well between tuberculous and neoplastic effusions. 
P.C. Mathur et al51. studied 50 cases of tuberculous pleural effusion and found that,ADA 
was found positive with a mean value of 100U/L tubercular pleural effusion, with overall 100% 
sensitivity and 94.6% specificity with a cutoff value of 40 U/L. 
Burgess L.J.48 showed ADA activity in tuberculous effusion was higher than in any other 
diagnostic group. At a level of 50U/L the sensitivity and specificity for the identification of 
tuberculosis was 90% and 89% respectively. 
Significance of ADA activity and its isoenzymes(ADA-1m, 1C and ADA-2) in pleural 
effusion was studied by Carstens ME et al54. He concluded that determination of paterns of ADA 
isoenzymes doesn’t enhance the overall diagnostic value of ADA activity in pleural effusion. 
Value of ADA activity in pleural effusion was studied by Shibagaki T et al.55 He 
concluded that tuberculous pleural effusion had a much higher ADA activity than cancer 
effusion and total ADA activity in tuberculous pleural effusion decreases after anti tubercular 
therapy. 
Voight56 studied 41 cases with bacteriologically confirmed tuberculosis and 41 cases with 
other causes. The mean ADA level for tubercular etiology was 99.8 U/L with sensitivity and 
specificity for diagnosis of tuberculosis was 95% and 98% respectively. 
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Cochrane meta-analysis shows that the test results for ADA with cutoff value > 40 U/L  
derived from the SROC curve was 92.2% for both sensitivity and specificity. 
The two main diseases other than tuberculous pleuritis that are associated with a high 
pleural fluid ADA are empyema and rheumatoid pleuritis. However,these two diseases can be 
differentiated from  tuberculous pleuritis by the clinical picture and the fact that these latter two 
diseases do not have pleural fluid lymphocytosis. Indeed, if the diagnostic criteria for 
tuberculous pleuritis includes a pleural fluid lymphocyte-to-neutrophil ratio of 0.75 or more, the 
specificity of the test is increased14,57,53. An ADA level <40 IU/L virtually excludes tuberculosis 
in lymphocytic pleural effusions. Immunosuppressed patients with tuberculous pleuritis have 
elevated pleural fluid ADA levels. The levels of ADA in patients with and without AIDS are 
comparable42. Renal transplant patients who develop a pleural effusion have elevated pleural 
fluid ADA levels58 . Pleural fluid adenosine deaminase level of more than 100 IU/L is 100% 
specific for tubercular effusion. 
An elevated pleural fluid ADA level in countries with a high prevalence of tuberculous 
pleural effusions has a high degree of specificity for tuberculous pleuritis, which makes it an 
integral part of the diagnostic work-up of lymphocyte-rich pleural effusions. The sensitivity and 
specificity of ADA depends on the prevalence of tuberculosis in the population. With the decline 
in the prevalence of tuberculous pleural effusion, the positive predictive value of pleural fluid 
ADA also declines, but the negative predictive value remains high. So, the measurement of the 
pleural fluid ADA level is an excellent test to rule out a tuberculous etiology of pleural effusion, 
irrespective of the rate of prevalence of the disease35,38.  
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In areas in which the prevalence of disease is low, there is a higher likelihood of false-
positive test results, and this can lead to the unnecessary administration of antituberculous 
therapy or a delay in making an alternative diagnosis such as malignancy. Another potential 
problem in the use of ADA is in patients with drug-resistant tuberculosis who may get treated 
inadequately because of the lack of immediate availability of culture and drug-sensitivity results.  
The consequence of a false-positive test result that may cause delay in the diagnosis of malignant 
pleural effusion, an incurable condition, is not as significant as missing a potentially curable 
tuberculous effusion. 
 
Interferon-gamma: 
  Interferon-gamma is produced by the CD4+ lymphocytes from patients with tuberculous 
pleuritis46,59,60. Patients with tuberculous pleuritis tend to have higher pleural fluid interferon-
gamma levels than do patients with pleural effusions of other etiologies. Villena et al61 measured 
the pleural fluid interferon-gamma levels in 595 patients, including 82 with TB, and reported that 
a cutoff level of 3.7 IU/mL yielded a sensitivity of 0.98 and a specificity of 0.98.  Patients with 
empyema frequently have elevated pleural fluid levels of interferon-gamma46. Patients with 
tuberculous pleuritis tend to have higher pleural fluid interferon-gamma level than do patients 
with pleural effusions of other etiologies.  
Studies comparing ADA and IFN-γ simultaneously in the same set of patients have 
reported both ADA better than IFN-γ and IFN-γ better than ADA as diagnostic markers. In fact, 
a meta-analysis by Greco et al62  regarding the diagnostic accuracy of ADA vs IFN-γ included 31 
studies in favor of ADA (total, n = 4,738) and 13 studies in favor of IFN-γ (total, n = 1,189). 
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Using summary receiver operating characteristic curve, they found only a marginal difference in 
overall sensitivity and specificity: 93% for ADA, and 96% for IFN-γ. Using Bayes theorem, the 
posttest probability of a negative test result was calculated. The minute difference in post test 
probabilities (ADA vs IFN-γ, 0.4% vs 0.22%, 2.4% vs 1.2%, and 24% vs 17%) was maintained 
over a wide prevalence range of 5 to 85%. The authors concluded that “ADA and IFN-γ appear 
to be reasonably accurate at detecting TB pleurisy.” Virtually similar sensitivity and specificity 
coupled with lower cost should favor the use of ADA as a diagnostic tool compared to IFN-γ. 
TB polymerase chain reaction: 
Querol et al.63 performed PCR on the pleural fluid from 21 patients with pleural TB and 
86 controlsand reported that the sensitivity and specificity of PCR for the diagnosis of 
tuberculous pleuritis were 81% and 100% respectively. PCR has been much less accurate in 
other studies65.  
Villena et al.64 reported that  PCR was positive in only 42% of patients with tuberculous 
pleuritis. In two recent studies, PCR had a sensitivity of less than 20% for the diagnosis of 
tuberculous pleuritis65,66.  
It appears, however, that PCR is certainly not superior to either the pleural fluid ADA or 
interferon-gamma levels in establishing the diagnosis of tuberculous pleuritis. Currently, PCR of 
the pleural fluid should be considered to be an investigative test until there is more data available 
regarding its sensitivity and specificity. 
Other tests done in pleural fluid for the diagnosis of tuberculosis includes Tubercular 
protein, antibodies and CRP. These tests are more considered to be investigative tool without 
much clinical application. 
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HIV INFECTION67: 
Pleural effusion is seen in 7 – 25%  of patients hospitalized with HIV. The most common 
cause is Kaposi’s sarcoma followed by parapneumonic 
effusion,tuberculosis,lymphoma,cryptococosis and rarely pneumocystis infection. 
NEOPLASMS: 
Malignant pleural effusion secondary to malignancy are the second most common cause 
of exudative pleural effusion. They are the commonest cause of pleural effusion in the elderly 
after 60 years of age. Nearly 70 – 80% of all malignant efuusion are caused by bronchogenic 
carcinoma, breast carcinoma and lymphoma. Other causes include gastrointestinal malignancies 
like ovarian carcinoma, gasric carcinoma. 7% of patients exhibit unknown primary. Multiple 
myeloma very rarely present with bilateral pleural effusion and its presentation is a bad 
prognostic sign. 
Most patients complain of dyspnea out of proportion to  size of the effusion. The fluid 
may be serous, serosanguinous or haemorrhagic. Recovery of cells from pleural fluid,sputum or 
bronchial washings, biopsy of the pleura,lymph node or transbronchial or CT guided biopsy of 
the mass or excision biopsy of the lymph node is useful in the diagnosis. 
Malignant mesothelioma is a primary tumour of the pleura related mainly to Asbestos 
exposure. Patients complain of chest pain and dyspnea. Imaging may reveal pleural thickening, 
shrunken hemithorax, tracheal shift to the same side and effusion. Biopsy is necessary to 
establish the diagnosis. 
PARAPNEUMONIC EFFUSION: 
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Parapneumonic effusions are associated with bacterial pneumonia, lung abscess, or 
bronchiectasis. Patients with aerobic bacterial pneumonia and pleural effusion present with an 
acute febrile illness consisting of chest pain, sputum production, and leukocytosis. Patients with 
anaerobic infections present with a subacute illness with weight loss, a brisk leukocytosis, mild 
anemia, and a history of some factor that predisposes them to aspirations.  The presence of free 
pleural fluid can be demonstrated with a lateraldecubitus radiograph, computed tomography (CT) 
of the chest or ultrasound. If the free fluid separates the lung from the chest wall by >10mm, a 
therapeutic thoracentesis should be performed. The concentration of pleural fluid 
myeloperoxidase and IL-8 helps to differentiate between complicated and uncomplicated pleural 
effusion. 
EMPYEMA: 
Empyema refers to a grossly purulent effusion. Clinically patients present with high 
grade fever, chest pain, cough with sputum expectoration and leukocytosis. Anaerobes, 
Staphylococcus aureus, Streptococcus pneumonia, E coli, Proteus are the common organisms 
causing emphyema.  
 
HYPOYTHYROIDISM: 
Myxedema is a well documented cause of serosal inflammation and pleural effusion is 
one of the manifestation of myxedema. Presentation is common in females and tell tale signs of 
myxedema like dry skin, puffy expressionless face and lethargy may be evident. Although 
transudative effusion is more common in myxedema, many authors have observed exudative 
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effusion68,69. High index of suspicion is necessary as this condition responds to hormone 
replacement and patient is spared from unnecessary drugs. 
PULMONARY EMBOLISM: 
Pulmonary embolism is one of the rare but commonly overlooked cause of pleural 
effusion. Dyspnea is the most common symptom. The pleural fluid is almost always an exudate 
rarely it can be transudative. It is usually haemorrhagic. The diagnosis is established by spiral CT 
scan or pulmonary arteriography. If the pleural effusion increases in size after anticoagulation, 
the patient probably has recurrent emboli or another complication such as a hemothorax or a 
pleural infection. 
 PLEURAL EFFUSION IN COLLAGEN VASCULAR DISEASES: 
Rheumatoid disease is complicated by an exudative pleural effusion with a 
characteristically low pleural fluid glucose level although in the initial stages glucose levels may 
be normal. The pathogenesis is nonspecific inflammation of visceral pleura and inflammation 
and thickening of parietal pleura, with numerous small vesicles or granules approximately 0.5 
mm in diameter73. Almost all patients with rheumatoid pleural effusions are older than 35 years 
of age, approximately 80% are men, and approximately 80% have subcutaneous nodules71,72,74,75. 
Examination of the pleural fluid reveals an exudate characterized by a low glucose level (<40 
mg/dL), a low pH (<7.20), a high lactate dehydrogenase (LDH) level (>700 IU/L or >2 times the 
upper limit of normal for serum), low complement levels, and high rheumatoid factor titers 
(>1:320)73. The pleural fluid differential can reveal predominantly polymorphonuclear or 
mononuclear leukocytes, depending on the acuteness of the process. 
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  Both systemic and drug-induced lupus erythematosus may affect the pleura. The pleura is 
involved more frequently in systemic lupus erythematosus (SLE) than in any other collagen 
vascular disease. Patients with lupus pleuritis have higher pleural fluid glucose levels (>60 
mg/dL), higher pleural fluid pH (>7.35), and lower pleural fluid LDH levels (<500 IU/L or <2 
times the upper limit of normal for serum) than patients with rheumatoid pleuritis75,76. Other 
immunologic tests are not generally recommended. 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
MATERIALS AND 
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MATERIALS AND METHODS 
STUDY PERIOD: 
August 2007 to September 2009. 
STUDY PLACE: 
Dept of General medicine,Govt Stanley medical college & Hospitals. 
Patients admitted in medical wards on Govt Stanley medical college with exudative pleural 
effusion were taken for study. 
 
INCLUSION CRITERIA: 
 1.Cases of Exudative pleural effusion. 
 2. Age >12 yrs. 
EXCLUSION CRITERIA: 
 1.Cases of Transudative pleural effusion. 
 2. Age <12 yrs. 
 3. Haemodynamically unstable patients. 
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DIAGNOSTIC CRITERIA: 
 Light’s criteria was used to diagnose exudative pleural effusion. 
Exudative pleural effusion meet atleast one of the following criteria: 
1. Pleural fluid protein/serum protein >0.5 
2. Pleural fluid LDH/serum LDH >0.6 
3. Pleural fluid LDH more than two-thirds of normal upper limit for serum. 
 
Criteria taken for diagnosis of  Tuberculous pleural effusion 
   Demonstration of AFB in pleural fluid/sputum 
  &/or ADA > 40 U/L  
   &/or L/N ratio >0.75 in pleural fluid. 
 In nontuberculous pleural effusion,following causes were evaluated. 
1.Lupus pleurisy was diagnosed based on ACR criteria for Systemic lupus erythematosis. 
2.Liver abscess was diagnosed based on clinical features and ultrasonography. 
3.Pneumonia was diagnosed based on clinical features, Chest imaging and CT, sputum gram   
stain and culture. 
4.Hypothyroidism was diagnosed with thyroid function tests and clinical features. 
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5.Malignancy was diagnosed with clinical features, imaging and biopsy reports. 
6.Emphyema was diagnosed based on clinical features, pleural fluid gram stain and culture 
7.Rheumatoid pleurisy was diagnosed based on ACR criteria for Rheumatoid arthritis and lab           
investigations of pleural fluid. 
 
The following data were noted: 
1. Age,sex,occupation. 
2. Clinical features – fever,cough,sputum,pleuritic chest pain,breathlessness,haemoptysis,weight 
loss,anorexia. Any other specific history is also noted like joint pain,alopecia,seizures,jaundice. 
3. Previous history of tuberculosis,contact with tuberculosis,diabetes mellitus,smoking and 
alcoholism were also noted. 
4. Investigations – Heamogram, ESR, blood urea, serum creatinine, liver function tests, mantoux, 
chest X ray, sputum AFB and culture & sensitivity was done in all cases. HIV ELISA was done 
in suspected cases and willing patients after counseling. Diagnostic thoracocentesis was done 
and fluid sent for analysis of glucose, protein, cytology and cell count, LDH ,AFB & gram stain, 
culture & sensitivity and ADA.  
5. Imaging – Plain chest X ray PA  view in all cases, USG chest and/or CT chest based on 
affordability. 
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6. Other investigations in appropriate cases – ECHO, Pericardial fluid analysis, serum HBsAg, 
Anti HCV, OGD scopy, serum ANA, dsDNA, RA factor, aCL antibody, Serum thyroid function 
tests, MRI brain, 24-hr urine protein, CD4 count, CT guided biopsy. 
 ADA in pleural fluid was done by sensitive Giusti’s calorimetric method. Total ADA was 
done. ADA 2 was not done. 
 
. 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
RESULTS  
  
37 
 
RESULTS 
 A total of 120 patients with exudative pleural effusion were analyzed,of which 83 were 
males and 37 females(table 1). Age distribution data shows that maximum number of cases were 
seen in age group between 21 and 40 yrs(Table 2). In our study the lowest age was 13 years and 
highest age was 76 years. 
Table 1:SEXWISE DISTRIBUTION 
Male Female Total 
83(69.1%) 37(30.9%) 120 
 
Table 2:AGEWISE DISTRIBUTION 
Age in years Male Female Total Percentage 
13-20 5 5 10 8.3% 
21-30 27 13 41 34.1% 
31-40 23 11 34 28.3% 
41-50 17 4 21 17.5% 
51-60 5 3 8 6.7% 
>60 5 1 6 5% 
 
Symptom analysis(Table 3) shows that Pleuritic type of chest pain is the most frequently 
noted symptom in 88 cases(73.3%), followed by fever in 74 cases(61.6%), dyspnea in 73 
cases(62%), cough in 69 cases(57.5%), anorexia in 47 cases(39.1%), weight loss in 38 
cases(31.6%), sputum production and heamoptysis in 33(27.5%) and 3 cases(2.6%) respectively. 
Chart 1:SEX RATIO
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Other symptoms noted are Intercostal tenderness in 3 cases of emphyema, axillary 
lymphadenopathy in 3 cases, arthralgia in 4 cases of connective tissue disease and seizures in one 
case tuberculous pleural effusion with tuberculoma of brain. 
 
Table 3:CLINICAL FEATURES-SYMPTOMS 
Symptom Total Percentage 
Pleuritic chest pain 88 73.3% 
Dyspnoea 73 62% 
Fever 74 61.6% 
Cough 69 57.5% 
Weight loss 38 31.6% 
Appetite loss 47 39.1% 
 
In our series,of 74 cases with fever,37(50%) cases presented with symptoms of less than 
3 weeks duration and of 69 cases with cough,34(49.1%) had symptom for less than 3 weeks 
duration. Only 33 cases(47.8%) with cough produced sputum. 3 cases presented with 
haemoptysis,1 each due to tuberculosis,pneumonia and malignancy. 
In our study, left sided effusion was seen in 61 cases(50.8%), right sided effusion in 55 
cases(45.8%) and bilateral effusion in 4 cases(3.6%)(Chart 3). Of those cases with bilateral 
effusion 3 were due to connective tissue disease and one due to tuberculosis. Majority of the 
effusions were moderate in quantity by clinical examination and imaging.. 
Chart 2:CLINICAL FEATURES- SYMPTOMS
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 The mean haemoglobin was 10.7 gm/dl and 67 cases had haemoglobin less than 11 
gm/dl(Table 4). Total WBC count in peripheral blood ranged between 2,800 to 21,000 with 
lowest value noted in malignant effusion and highest value in tuberculous effusion. The 
differential count of peripheral blood was not informative. 
Table 4:HAEMOGRAM 
Heamoglobin(G/dL) Male  Female Total 
Range 6.8-15.6 5.3-13.8 5.3 – 15.6 
Mean 10.68 10.5 10.7 
 
Table 5:ESR RANGE AND MEAN 
ESR(mm) 30 minutes 60 minutes 
Range 5 - 65 12 – 148 
Mean 28 57 
 
The ESR was elevated (Table 5)with a mean of 28 mm at 30 minutes and 57 mm at one 
hour.  
Analysis of pleural fluid revealed that gross appearance of the fluid was straw coloured in 
69 cases(57.5%), clear in 21cases(17.5%), heamorrhagic in 12 cases(10%), cloudy in 
5(4.1%),purulent in 4(3.6%),bloody in 3 and high coloured in 1 case respectively. Pleural fluid 
was purulent in 3 cases of emphyema and one case of tuberculous effusion. Bloody tap was 
found in malignant effusion, high coloured fluid in effusion secondary to amoebic liver abscess. 
Chart 3: SIDE OF INVOLVEMENT
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 Pleural fluid glucose ranged between 13 to 142 mg/dl,with a mean value of 76.7 
mg/dl. Lowest value was 13 mg/dl found in rheumatoid pleural effusion. Pleural fluid was sent 
for Gram stain, AFB stain and culture. None of the sample tested positive for AFB stain. 3 cases 
of emphyema stained positive for organisms in Grams stain of which one was culture positive for 
Pseudomonas.  
ADA was done in all samples of pleural fluid. Total ADA was done. ADA 1 &2 isoforms 
was not done. 
The range of ADA was between 5 to 239 U/L with a mean ADA value of 89.58 
U/L(Table 6). ADA was > 40 U/L in 100 cases(Table 7). L/N ratio was done in all cases. L/N 
ratio was >0.75 in 97 cases(Table 8). Based on ADA and L.N ratio 97 cases were classified to 
have Tuberculous pleural effusion. Other causes of exudative effusion noted are 7 cases of lupus 
pleurisy, 5 parapneumonic effusion, 3 malignant effusion, 2 rheumatoid pleurisy, 3 emphyema, 2 
hypothyroidism and 1 case of liver abscess with exudative effusion. 
 
Table 6:TOTAL ADA RANGE AND MEAN 
ADA range(U/L) 5 – 239 
ADA mean(U/L) 89.58 
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Table 7:ADA 
 ADA < 40 U/L ADA > 40 U/L 
No of cases 20 100 
 
Table 8:L/N RATIO 
 L/N ratio > 0.75 L/N ratio< 0.75 
No of cases 97 23 
 
 
Of  97 cases of tuberculous pleural effusion, males were 70 in number and females 
27(Table 9). The most common age group of presentation with illness was 21 – 40 years and the 
mean age was 26.6 years. Pleuritic chest pain was noted in 64 cases, followed by fever in 62 
cases, cough in 59 cases and sputum in 28 cases, haemoptysis in 1 case. Past history of 
tuberculosis was obtained in 7 cases and history of contact with TB patients in 14 cases(Table 
10). Mantoux was reactive(10mm or more)in 52 cases(Table 11). 50 cases presented with left 
sided effusion and 54 patients had moderate effusion. Sputum smear for AFB was done in 33 
patient  who produced sputum and it tested positive in only 3 cases. 
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Table 9:GENDERWISE DISTRIBUTION OF ETIOLOGY OF PLEURAL EFFUSION. 
Etiology Male Female Total 
Tuberculous effusion 70 27 97 
Parapneumonic effusion 3 2 5 
Malignant effusion 3 0 3 
Rheumatoid pleurisy 1 1 2 
Lupus pleurisy 0 7 7 
Emphyema 2 1 3 
Hypothyroidism  2 0 2 
Liver abscess 1 0 1 
TOTAL 83 37 120 
  
 
Table 10:PAST H/O AND CONTACT WITH TB 
Past H/O TB 7(7.2%) 
H/O contact with TB 14(14.5%) 
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Table 11: MANTOUX AND SPUTUM AFB IN TPE 
 Tested Positive 
Mantoux 97 52(53.6%) 
Sputum AFB 28 3(10.7%) 
 
Total ADA was done and found to be > 40 U/L in all the cases with Tuberculous pleural 
effusion. The mean ADA was 153.6 U/L. the highest value noted in our study was 239 U/L, and 
the lowest was 42.19 U/L(Table 12). ADA value > 100U/L was noted in 36 cases. 
In exudative effusion due to other causes, total ADA was done. It was found that the 
ADA value ranged between a lowest of 5 U/L to a highest of 76.5 U/L. The mean ADA value 
was 25.6 U/L. Of 23 cases, 3 cases had ADA >40 U/L(1 Rheumatoid arthritis with pleural 
effusion, 1 malignant effusion and 1 hypothyroid effusion), rest 20 cases had ADA < 40 U/L. 
 
Table 12:ADA IN EXUDATIVE EFFUSION 
ADA(U/L) Tuberculous effusion Nontuberculous effusion 
Range 42.19 – 239 5 – 76.5 
Mean 153.6 25.6 
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Table 13:L/N RATIO IN EXUDATIVE FFUSION 
L/N Ratio Tuberculous effusion Nontuberculous effusion 
>0.75 97 0 
<0.75 0 23 
 
All cases of tuberculous pleural effusion were lymphocyte predominant with a (L/N) 
Lymphocyte/Neutrophil ratio of  >0.75. In cases of exudative pleural effusion due to 
nontuberculous etiology L/N ratio was < 0.75 cases(Table 13).  
All cases of Tuberculous pleural effusion had ADA > 40 U/L and L/N ratio > 0.75. of 23 
cases with nontuberculous pleural effusion, Ada was < 40 U/L in 20 cases and L/N ratio was < 
0.75 in all 23 cases. 
Table14:ADA AND L/N RATIO 
Etiology ADA >40U/L L/N ratio >0.75 
Tuberculous 97 97 
Non tuberculous 3 0 
 
 
Renal failure(Serum creatinine >1.5mg/dl)was noted in 3 cases. Two of them were long 
standing diabetics and suffered from tuberculous pleural effusion. Both the cases were managed 
conservatively. One case of emphyema had  Acute kidney injury and renal function reverted to 
normal with adequate rehydration and attention to the primary cause. One patient with Amoebic 
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liver abscess had Total bilirubin of 4.3 mg/dl with a direct fraction of 2.3 mg/dl. Nutritional 
status as assessed by serum albumin was fairly normal.  
. Sputum cultured for bacteria was positive in 5 cases due to parapneumonic effusion. 
Pneumococci was the most common organism obtained in culture(3 cases). 
HIV was tested in 103 patients and 2 cases tested positive. Both cases presented with low 
grade fever and pleuritic chest pain and their pleural fluid analysis including ADA vaue did not 
differ significantly from others. 13 diabetics participated in our study and all were on oral 
antidiabetic drugs. Out of them 8 cases had tuberculous pleural effusion,2 malignant effusion,2 
cases effusion secondary to connective tissue disease and 1 case had emphyema. 
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DISCUSSION 
Tuberculosis is a common infection in India and the commonest cause of exudative 
pleural effusion. Definitive diagnosis of TB pleural effusion is difficult. Pleural fluid Acid Fast 
Bacilli(AFB) demonstration is virtually always negative, culture of fluid could be positive in 
<25%, histology(HPE) of pleural biopsy could be positive in 80% whereas HPE and culture of 
pleural biopsy increases diagnostic efficacy to 90%26. Because of the non-availability of 
confirmatory tests(Pleural biopsy and HPE) in all centres, the confirmation of diagnosis is 
difficult. In India,an exudative pleural effusion is considered Tuberculous and started on 
Antituberculous Treatment(ATT).  
ADA is considered a valuable tool in the diagnosis of Extra-pulmonary Tuberculosis. The 
measurement of the pleural fluid ADA level could be used to rule out a tuberculous etiology of 
lymphocytic pleural effusions. In areas with a high prevalence of tuberculosis, the  proportion of 
false-positive results will be obviously lower. With the decline in the prevalence of Tuberculous 
pleural effusion(TPE), the positive predictive value of pleural fluid ADA also declines, but the 
negative predictive value actually increases. Therefore, the measurement of the pleural fluid 
ADA level could be used to rule out  tuberculous etiology of lymphocytic pleural effusions, 
regardless of the rate of prevalence of the disease35,38.  
Cochrane meta-analysis review of forty articles on ADA in pleural fluid shows that the 
test results for ADA with cutoff value > 40 U/L  derived from the summary receptor operator 
curve(SROC) was 92.2% for both sensitivity and specificity. Specificity is increased when the 
lymphocyte/neutrophil ratio in the pleural fluid (> 0.75) is considered together with an ADA 
concentration of > 40 U/L57. Hence, though ADA assay should not be considered as an 
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alternative to biopsy and culture, it is a simple,inexpensive, highly sensitive and specific test that 
can be employed routinely to differentiate between tubercular and non-tubercular etiology in 
patients of exudative pleural effusion and to guide further diagnostic procedures and 
management of an exudative pleural effusion of unknown origin. With this background  this 
study was undertaken to evaluate the role of ADA and L/N ratio in the  diagnosis of Tuberculous 
pleural effusion in patients with exudative effusion.   
A total of 120 cases with exudative pleural effusion were taken for study. Males 
constituted  83 cases and females 37 cases. 97 cases had effusion due to tuberculous etiology. 
Study shows that most of the cases were found in males in their  middle age between 21 – 40 
years. 
TUBERCULOUS PLEURAL EFFUSION: 
97 cases of tuberculous pleural effusion were analysed. Males constituted to 61 in 
number and females 26. The most common age group was between 21 – 40 years of age with a 
mean age of 26.6 years. This is consistent with the study by  Shibagaki T et al.,55 which shows 
that the most common age group of presentation of tuberculous pleural effusion is 20 – 40 years.  
The most common symptom seen was pleuritic chest pain, seen in 64(65.9%)cases. This 
is similar to the study of  Moudgil H et al22., and Richter C et al24., where nearly 70% had a 
cough, usually nonproductive, and 68% had chest pain, usually pleuritic in nature. Although TB 
is usually considered a chronic illness, tuberculous pleuritis most commonly manifests as an 
acute illness.  
In our study, of 62 patients who had fever,39(62.9%) had fever for less than 3 weeks 
duration and 23 cases(37.1%) had fever for more than 3 weeks. We found this pattern similar to 
48 
 
that of the study by Berger HW et al17, in whose series, 31 of 49 patients (63%) had an acute 
illness that most commonly mimicked acute bacterial pneumonia. 
Cough was noted in 59 cases(60.8%), of them 32 cases had cough less than 3 
weeks(54.2%). Sputum production was seen in 28 cases(28.8%). One case of tuberculous pleural 
effusion had haemoptysis and CT scan showed parenchymal lesions in him. Anorexia was seen 
in 41 cases(42.3%) and significant weight loss was noted in 28 cases(29%).  
Past history of tuberculosis was elicited in 7 cases and one case gave history of primary 
complex in childhood. 4 cases had parenchymal disease and 3 cases had tuberculous pleurisy. 
Two cases were defaulters, rest all completed full course of treatment. History of contact with 
tuberculosis was noted in 14 cases. 
Of 97 cases with tuberculous pleural effusion, 37(38.2%) cases were smokers, 35(32.6) 
consumed alcohol and 9(9.2%) cases were diabetics. The mean haemoglobin was 8.58 g/dl, ESR 
was 31 mm at 30 minutes and 63 mm at 60 minutes. The total WBC count ranged between 4,200 
– 21,000 cells/mm3. 
Two cases of tuberculous pleural effusion had renal failure with serum creatinine > 1.5 
mg/dL. Both the patients had diabetes and imaging showed medical renal disease. Both the cases 
were managed conservatively. Nutritional status as assessed by serum protein was satisfactory. 
Mantoux reaction was positive in only 52(53.6%) of 97 cases. In a report Fujiwara H et 
al, approximately 1 in 2,000 of the lymphocytes in the pleural fluid was specifically sensitized to 
tuberculous protein, whereas only 1 in 15,000 of the lymphocytes in the peripheral blood was 
specifically sensitized to the tuberculous protein77. T lymphocytes specifically sensitized to 
tuberculous protein are present in the pleural fluid than in peripheral blood. If a patient with a 
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negative tuberculin skin test and tuberculous pleuritis is skin tested more than 8 weeks after the 
development of symptoms, the skin test will almost always be positive78. Sputum for AFB was 
done in 28 patients who had productive cough and it was positive in 3 cases, who had 
concomitant parenchymal involvement. 
The gross appearance of the pleural fluid was straw coloured in 35 cases(36.08%), clear 
in 53 cases(54.6%), haemorrhagic in 10 cases(8.3%) and cloudy in 1 case. The glucose values 
ranged between 16 – 225 mg/dl,with an average of 82mg/dl. Pleural fluid glucose concentration 
was <30 mg/dl in 18(17%)cases and > 60 mg/dl in 79(83%) cases. This observation is consistent with 
the study of  Epstein DM et al31., where the pleural fluid glucose concentration is > 60mg/dL in 
80 to 85% of cases and <30 mg/dL in approximately 15% of cases.(21) The lowest value of pleural 
fluid glucose was found in Rheumatoid pleurisy(13 mg/dl).  Pleural fluid AFB staining was 
negative in all 97 cases and is consistent with the demonstration by  Light RW26. 
All the 97 cases had Lymphocyte predominant pleural effusion with a L/N ratio >0.75. 
Total ADA was done in all cases and found to be >40 U/L in all the cases. The range of ADA 
was between 42.19 – 239 U/L with a mean of 153.6 U/L. These results are in agreement with 
those of  P.C. Mathur et al51., in whose study of tuberculous pleural effusion,ADA ranged from 
45-160 U/L with a mean level of 100U/L. P.C. Mathur also observed in his study that, with a 
cutoff value of >40 U/L the sensitivity and specificity for diagnosing tubercular effusion was 
100% and 94.6% with positive and negative predictive values of 95.5% and 100% respectively.  
Although the rise in ADA in tuberculous pleural effusion was predominantly due to 
ADA-2, the difference was statistically not significant and measurement of ADA isoforms is 
commercially not feasible as observed by Cartens et al54. An ADA level <40 IU/L virtually 
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excludes tuberculosis in lymphocytic pleural effusions. Jimenez Castro et al.36 measured the 
pleural fluid ADA levels in 410 lymphocytic nontuberculous pleural fluids and found that the 
ADA was above 40 U/L in only 7 (1.7%). The negative predictive value of ADA for the 
diagnosis of pleural tuberculosis was 99% in his study. Pleural fluid ADA level of more than 100 
IU/L is 100% specific for tubercular effusion. 
All cases with TB pleural effusion were lymphocyte predominant with a L/N ratio > 0.75. 
The combined use of ADA and L/N ratio increases the specificity of ADA as observed by  
Burgess LJ et al57. This increase in specificity is due to excluding the cases with rheumatoid 
pleuritis or empyema. 
75 cases had isolated pleural effusion detected by clinical and/or radiological methods. 2 
cases had pericardial effusion along with pleural effusion. 10 cases had parenchymal 
involvement in addition to pleural disease, of which pneumonitis was seen in 3 cases, fibrosis in 
4 cases, fibrocavity in 1 case and cavity in 2 cases. 1 case had tuberculoma of the brain. Mitral 
valve prolapse was found in 1 patient who also had history of palpitation. 1 patient was an 
inactive carrier of  Hepatitis B virus with normal liver enzymes and low DNA count. 2 cases of 
alcoholic compensated liver disease were seen.  
2 cases of TB pleural effusion with HIV were studied and the analysis reveals that ADA 
in them was > 75 U/L and L/N >0.75. This is in line with the observation by Riantawan P et al., 
who observed that the levels of ADA in patients with and without AIDS are comparable (59). 
The most common socioeconomic risk factor in the occurance of tuberculus pleural 
effusion in our study was Poor socioeconomic status.  
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All cases of isolated pleural effusion were administered ATT under standard category III 
DOTS regimen and advised follow-up after 1 month,2 month and completion of course. Cases 
who were sputum positive for AFB were given category I DOTS. Those with pericardial 
involvement were administered ATT under category I dots with oral prednisolone for 6 weeks 
and followed up as before. All cases with co-morbid conditions were managed individually and 
ATT doses were adjusted as necessary. Close follow-up for this patients were done. It was 
observed that the average time for resolution of TB pleural effusion was 1 – 2 months and it did 
not differ in HIV patients also.  
NONTUBERCULOUS EXUDATIVE PLEURAL EFFUSION: 
RHEUMATOID PLEURISY: 
2 cases of exudative pleural effusion due to Rheumatoid Arthritis was seen. The average 
age of presentation was 40.5 years and 1 patient was male and other female. Pleuritic chest pain 
was noted in both the patients and one patient had cough. Both patients had history of long 
standing bilateral small joint arthritis. 
The lowest level of pleural fluid glucose in our study was noted in rheumatoid pleurisy, 
the value being 13 mg/dl. In both the cases pleural fluid LDH level were elevated than plasma 
levels and Rheumatoid factor(RA) level was > 1:320 in pleural fluid. This is in accordance with 
the observation of Halla JT et al75. 
The mean ADA value was 42.50 U/L and one case had elevated ADA 69 U/L. The 
effusion were Lymphocyte predominant but none of them achieved L/N ratio >0.75. 
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The diagnosis in these cases were proven with investigations and criterion in accordance 
with ACR criteria. Anti-inflammatory agents(NSAID) with low dose(10 mg)Prednisolone and 
Methotrexate(12.5 mg weekly)were prescribed. The average time for resolution of effusion was 
between 1-4 months. 
LUPUS PLEURISY: 
 7 cases of exudative pleural effusion due to Systemic Lupus Erythematosis(SLE) was 
noted. All patients were females with an average age of 34.5 years.  The most common symptom 
noted was pleuritic chest pain in 6 cases(85.6%), followed by cough and fever in 2 cases each. 
Musculoskeletal symptoms were the predominant systemic compliants with arthralgia and 
myalgia noted in 4 cases. Oral ulcers, malar rash and photosensitivity rash was seen in 1 cases 
each. Alopecia was noted in 2 cases.   
 1 case of lupus pleural effusion was an elderly female(56 years) who had lupus 
pneumonitis,nephritis and dermatitis. 1 case had isolated pleural effusion,2 cases had pleural and 
pericardial effusion, 1 case had cardiomyopathy,1 case had pleural effusion with 
antiphospholipid antibody syndrome and 1 case presented with seizures,pleural effusion,high 
lateral myocardial ischaemia,LV clot and thrombocytopenia and secondary Antiphospholipid 
antibody syndrome(APLA)–a Hughes syndrome.  
The average pleural fluid glucose level was 76 mg/dl. The mean ADA value was 17.65 
U/L and none of the cases had ADA > 40 U/L. The effusion were lymphocytic but none of the 
cases had L/N ratio > 0.75. 
The diagnosis in these cases were proven with investigations and criterion in accordance 
with ACR criteria. Cases of SLE with life-threatening complications were treated with parentral 
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methyl prednisolone followed by oral cyclophosphamide, others with oral prednisolone. Patient 
with APLA syndrome was treated with heparin followed by oral warfarin along with oral 
prednisolone. The average time for resolution of effusion was between 1-4 months. 
PARAPNEUMONIC EFFUSION: 
5 cases of Pneumonia with pleural effusion were analysed. The presentation was like 
acute illness and presenting complaints were fever(80%), cough with sputum production(100%), 
pleuritic chest pain(60%) and dyspnea(60%). Haemoptysis was seen in 1 patient.  
The mean WBC count was 12,400 and peripheral blood neutrophilia was noted in line 
with the observation of Light RW et al10. Pneumococci was grown in sputum of 3 cases and 
klebsiella along with E coli in 2 cases. This observation is consistent with the study of  Varkey B 
et al80., and Bartlett JG et al79., who stated that Pneumococci and S aureus account for 
approximately 70% of all aerobic gram-positive isolates and E coli along with Klebsiella sp 
account for approximately 75% of all aerobic gram-negative empyemas.  
The mean glucose level in pleural fluid was 52 mg/dl. The pleural effusion was 
neutrophil predominant with a L/N ratio<0.75. Culture of pleural fluid was negative in all the 
cases. The ADA level was < 40 U/L in all the cases with a mean value of 21.3 U/L.  
The parapneumonic effusion were classified as class 2 Typical parapneumonic effusion 
according to Light’s classification and category 2 parapneumonic effusion according to ACCP 
guidelines in all the cases. Patients were treated conservatively with parentral Antibiotics based 
on sensitivity pattern and prompt resolution of infection was seen 48 – 72 hours and pleural 
effusion resolved in a mean duration of 17 days. No mortality was noted.  
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EMPHYEMA: 
Emphyema was noted in 3 cases. The most common presenting symptom was 
fever(100%),cough(66%) and pleuritic chest pain(66%),Intercostal tenderness was noted in all 
cases(100%). One patient presented with subacute illness of fever of > 3 weeks duration. The 
mean WBC count was 12,600 with predominant neutrophils. 
Gross appearance of pleural fluid was purulent in all the cases. Mean pleural fluid 
glucose concentration was 50 mg/dl. In our study ADA value was less than 40 IU/L and L/N 
ratio <0.75.in all the cases. Mean ADA value was 27 U/L. Gram’s stain of pleural fluid was 
positive for Gram negative organism in all 3 cases and 1 case had growth of Pseudomonas in 
pleural fluid. 
One patient had history of reduced urine output and serum creatinine was 1.6 mg/dl. He 
was rehydrated with intravenous fluids and with conservative management serum creatine 
became normal. Patients were treated with Antibiotics based on sensitivity pattern and Tube 
thoracostomy was done in all cases to evacuate pus and prompt resolution occurred. No mortality 
was noted.  
MYXOEDEMA: 
Exudative pleural effusion was noted in 2 cases of hypothyroidism. Both cases were 
females and average age was 51.5 years. Presenting symptoms were dyspnoea in both the cases 
and anorexia in 1 case. One patient had signs of hypothyroidism like dry skin and puffy face. 
Pleural fluid analysis revealed exudative effusion with average glucose values of 66 mg/dl.  
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Mean ADA was 57.3 U/L and 1 case had ADA of 75.6 U/L and the other 38.2 U/L.  
Effusion was lymphocyte predominant but L/N ratio was <0.75 in both cases. Their thyroid 
status was proved with the help of investigations and cases responded dramatically to Thyroxine. 
Though myxedema is a cause for transudative pleural effusion, exudative effusion can also be a 
feature of myxedema as observed in our study and also demonstrated by  Hataya Yuji et al68., 
and Gottehrer A et el69. High index of suspicion is needed to make a diagnosis of exudative 
pleural effusion due to hypothyroidism. 
EXUDATIVE PLEURAL EFFUSION IN LIVER ABSCESS: 
1 patient, an alcoholic presented with pain Right hypochondrium and jaundice and 
pleuritic chest pain. Evaluation revealed tender hepatomegaly and pleural effusion on right side. 
USG abdomen revealed multiple liver abscess and pleural fluid was high coloured. Effusion was 
exudative with ADA value of 6.7U/L and L/N ratio <0.75. Pleural fluid staining was negative for 
amoebic forms. Patient improved with Metronidazole in standard doses of 750 mg tds with 
paramomycin 500 mg bd for 10 days. 
MALIGNANT EFFUSION: 
Malignant effusion was noted in 3 cases of males. The average age of presentation was 
65 years. Smoking history was obtained in all of them and the average pack years was 22. None 
of them had exposure to suggest asbestosis. The most common symptom noted was anorexia and 
weight loss in all the three cases. 1 patient presented with haemoptysis. Mean haemoglobin was 
6.9 g/dl and mean ESR was 32 mm at 30 minutes and 68 mm at 60 minutes.  
Gross appearance of pleural fluid was bloody in 3 cases. ADA in pleural fluid was less 
than 40 IU/L in 2 cases(7.2 and 30.2   u/ l) and 42.6 U/L in one case. Mean ADA was 20.3 U/L. 
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The effusion was lymphocyte predominant with Mesothelial cells >10% and L/N ratio < 0.75 in 
all the three. Imaging showed hard craggy mass in pulmonary parenchyma consistent with 
malignancy in all the 3 cases. CT guided biopsy was done in 2 cases, one of which showed small 
cell variant and the other squamous cell varient. Third case presented with hard lymph node in 
left supraclavicular region,biopsy of which showed squamous cells with epithelial pearls and 
keratinization. Cases were given palliative care and referred for further care. 
 
SUMMARY: 
1. Total ADA in pleural fluid of more than 40 IU/L with a pleural fluid L/N ratio of more than 
0.75 is useful in differentiating between tubercular and non-tubercular pleural effusion. 
2. Tuberculosis is the most common cause of exudative pleural effusion. 
3. Peak age of Tuberculous pleural effusion is between 21 - 30 yrs. 
4. Males are affected more than females probably because of increased exposure to known 
and/or unknown infected cases. 
5. Most common symptom is pleuritic chest pain. 
6. Overall left sided effusion are more commoner than right sided effusions. 
7. Other causes of exudative pleural effusion noted are parapneumonic effusion, Connective 
tissue diseases, Malignancy, Amoebic liver abscess, Emphyema and Hypothyroidism. 
 
  
 
 
CONCLUSION 
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CONCLUSION 
120 cases of exudative pleural effusion were analysed based on Total ADA and L/N 
ratio. 97 cases were due to tuberculosis, 7 lupus pleurisy, 5 parapneumonic effusion, 3 malignant 
effusion, 3 emphyema,2 rheumatoid pleurisy, 2 myxoedematous pleural effusion and 1 exudative 
effusion in liver abscess. ADA level was > 40 U/L in 100 cases of which 97 were due to 
tuberculosis, 1 rheumatoid pleurisy, 1 malignant effusion and 1 case of effusion in myxedema. 
ADA value of   >100 U/L was observed only in tuberculous effusion. L/N ratio was >0.75 in 97 
cases of  TB effusion and in none of the nontuberculous effusion. Combined use of ADA and 
L/N ratio is more useful in the evaluation of exudative pleural effusion. 
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PROFORMA 
Name:   
Age:   Sex:   I.P.No: 
Symptoms: 
Chest pain:Yes/No 
         Duration 
Nature 
Radiation 
Aggrevating Or Relieving factors 
 
Fever: Yes/No 
  Duration 
Character 
Associated symptoms 
 
Cough: Yes/No 
  Dry/Productive 
Duration 
Aggrevating or relieving factors 
  Colour of the sputum 
Quantity 
Smell 
 
Breathlessness: Yes/No 
  Grade 
Aggrevating or relieving factors 
 
Haemoptysis: Yes/No 
  Duration 
Amount 
Colour 
Giddiness/Palpitation 
 
Anorexia: Yes/No 
 Weight loss: Yes/No 
 
Other symptoms: Myalgia, Arthralgia, Oral ulcers, Skin rashes. 
 
Past history: 
H/O of TB,Contact with TB,DM,SHT 
 
Personal history: 
H/O smoking/pack years,Alcoholism,Substance abuse 
 
Family History: 
Treated or open TB 
 
Investigations: 
Haemogram: Hb  TC  DC  ESR  Platelet 
Blood sugar  Serum Urea  creatinine  Electrolytes 
LFT:Bilirubin  AST  ALT  SAP  PT        Protein 
Chest radiograph PA 
 Lateral decubitus 
USG abdomen 
CT chest. 
Mantoux  HIV-ELISA  Sputum AFB   
Sputum Culture 
Pleural fluid analysis: 
 Glucose   protein   cellcount  
 Differential count   AFB    culture  
 L/N ratio   ADA    Gram stain 
Other investigations: 
 ANA,ds DNA,aCL,Ct guided biopsy and HPE 
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